[144/A] C3.ai, Inc. SEC Filing
Rhea-AI Filing Summary
C3.ai, Inc. (AI) filed a Form 144/A notifying a proposed sale of 470,420 shares of common stock to be executed on or about 10/01/2025 on the NYSE through Merrill Lynch, 520 Newport Center Drive, Newport Beach, CA. The filing lists an aggregate market value of $8,133,514.76 for the shares and indicates 134,349,704 shares outstanding. The securities were acquired on 10/01/2025 as a stock bonus from C3 AI Inc., with payment and acquisition dates shown as the same date. No sales by the reporting person in the prior three months are reported. The filer affirms they are unaware of any undisclosed material adverse information about the issuer.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider proposes to sell 470,420 shares valued at $8.13M, acquired as a stock bonus the same day.
This Form 144/A notifies a planned open-market sale executed through a major broker (Merrill Lynch) for 470,420 common shares with an aggregate market value of $8,133,514.76, to occur on or about 10/01/2025. The filing explicitly records the shares as acquired by stock bonus from the issuer on 10/01/2025 and states no sales in the prior three months. For investors, the filing documents supply-side pressure potential from an insider liquidity event, but provides no pricing or volume schedule details beyond the aggregate value and intended broker. The representation regarding lack of undisclosed material adverse information is standard.
TL;DR: Governance disclosure shows a same-day acquisition and proposed sale; filing includes required attestation.
The notice contains required disclosures under Rule 144: identity of broker, class, quantity, aggregate market value, outstanding shares, acquisition method (stock bonus), and an attestation that the seller is not aware of undisclosed material adverse facts. The acquisition and proposed sale dates both listed as 10/01/2025 are notable in the record and are presented without additional context about any trading plan or restrictions. The document contains no information on any 10b5-1 plan adoption date or other trading instructions.